Latest Inhaler Stories
REDWOOD CITY, Calif., June 16, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. today announced the advancement of its dual combination product candidate, PT003 and its individual components, PT001 and PT005 into a series of planned Phase 2 studies in patients with moderate-to-severe COPD.
According to new study, Respimat, a mist inhaler that delivers a widely-prescribed respiratory drug, increases the risk of dying by half.
People who use a mist inhaler to deliver a drug widely prescribed in more than 55 countries to treat chronic obstructive pulmonary disease (COPD) may be 52 percent more likely to die.
LISBON, Portugal, June 14, 2011 /PRNewswire/ -- Hovione announced today the international filing of its latest patent covering a new, highly efficient dry powder inhaler (DPI), XCaps. XCaps fills a void in the pulmonary inhalation market, as a device which combines high efficiency in powder dispersion with ease of use.
REDWOOD CITY, Calif., May 18, 2011 /PRNewswire/ -- Pearl Therapeutics Inc.
Nicotine-free plastic inhalers may increase a smoker's chance of quitting, according to new research published online in the European Respiratory Journal.
A new study shows a rarely-prescribed drug is easier to use and may be just as effective as treatment with inhalers.
A rarely prescribed asthma drug is easier to use and just as effective as conventional treatment with inhalers.
A British study published in the New England Journal of Medicine (NEJM) suggests that pills marketed under brand names such as Singulair and Accolate work just as well as inhalers
REDWOOD CITY, Calif., May 5, 2011 /PRNewswire/ -- Pearl Therapeutics Inc.
- A serpent whose bite was fabled to produce intense thirst.
More Images (2 images) »